EN
SINOVAC Expands Strategic Partnership with Bio Farma, Bolstering Indonesia's Vaccine Supply
July 28, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a strengthened alliance with Indonesian state-owned biopharmaceutical company PT Bio Farma, marking another milestone in the two companies' joint efforts to serve Indonesia's domestic vaccine market as well as international market.
The partnership agreement was signed on July 27, during the Indonesia-China Healthcare and Biotech Investment Forum held in Chengdu, the capital city of Sichuan Province in southwest China. It was witnessed by Indonesian government officials that included Budi Gunadi Sadikin, Indonesian Minister of Health; Djauhari Oratmangun, Indonesian Ambassador to China; and Arsjad Rasjid, Chairman of the Indonesian Chamber of Commerce and Industry.
Bio Farma, Indonesia's single and largest state-owned biopharmaceutical company, is an integral strategic partner for SINOVAC. The two companies partnered to successfully arm Indonesia with over 280 million doses of the inactivated COVID-19 vaccine, CoronaVac®, employing an efficient dual-pronged approach that enabled local filling of SINOVAC's finished product. CoronaVac® was the first COVID-19 vaccine available in Indonesia, a critical step in bringing the pandemic under control and protecting local populations.
SINOVAC remains committed to growth within the Indonesian market. Several of its products are available in addition to CoronaVac®, including the inactivated hepatitis A vaccine Healive® and the inactivated EV71 vaccine Inlive®. SINOVAC also has plans to introduce future products, including its varicella, influenza, and pneumococcal polysaccharide vaccines, to meet the region’s healthcare needs and further enhance local and national public health efforts.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com